Myriad Genetics (MYGN) PT Raised to $35 at Leerink Partners, 'Core Business Still Stabilizing But GeneSight Remains Key LT'
Tweet Send to a Friend
Leerink Partners raised its price ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
